Global pandemics, like COVID-19, have always been a serious threat to the existence of mankind. This isn’t the first time and certainly, won’t be the last. Researchers around the globe are combining their efforts to develop a sustainable vaccine. In this attempt, the use of AI and machine learning has produced some desirable results.
It is no secret that technological evolution is playing a major role in our fight against COVID-19, with the healthcare industry exploring the usage of Artificial intelligence and other Machine learning techniques to improve the quality of treatment.
Early experiments in Machine Learning presented promising results with respect to COVID-19. From predicting the risk of the infection and severity of a case to predicting treatment outcomes, ML is being applied in a lot of situations. The possibilities are endless. Scientists believe that ML is vital in order to counter the pandemic. Perhaps with the right data set, skills, and research, ML can be used to save lives – now and in the future. In this regard, the National Institute of Health is pondering on the use-cases of ML for a breakthrough in COVID-19 research.
The National Institute of Health (NIH) is using Artificial Intelligence and Medical imaging under its newly launched Medical Imaging and Data Resource Center (MIDRC). The multi-institutional partnership led by the NIBIB, a member of the National Institute of Health, will develop innovative methods for early diagnosis and tailored care of patients with COVID-19. Bruce J. Tromberg, Ph.D., NIBIB Director stated:
The medical images of the diseased lungs and hearts will be examined thoroughly to identify the severity of the disease. Moreover, the patient’s response can be predicted thereby improving the chances of a favorable outcome.
The MIDRC intends to pursue innovative development and deployment of technology, including machine learning techniques. This will enable the fast and precise analysis of the status and extent of the disease. In addition, the MIDRC allows fast and scalable acquisition, interpretation, and dissemination of clinical data.
The National Institute of Biomedical Imaging and Bioengineering (NIBIB), which is a part of the National Institute of Health, researches on the creation of new tools which will enable the provision of personalized therapies and the early and fast detection of COVID-19 patients.
However, the collection and continuous evaluation of data rapidly and accurately will facilitate optimum patient treatment.
Guoying Liu, Ph.D., who is leading the scientific program of the NBIB, said that “This effort will gather a large repository of COVID-19 chest images.” Not only will this enable researchers to analyze lung and cardiac tissue images, but will also make them ask important study questions and to build a predictive COVID-19 imaging signature that can be distributed to healthcare providers.